

#5
16425/3/02
83W
RECEIVED
APR 04 2002
TECH CENTER 1600/2900
PATENT



DOCKET NO.: JANS-0028

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:

Janssens et al.

Serial No.: 10/019,376 ✓

Group Art Unit: Not yet assigned

Filing Date: December 27, 2001 ✓

Examiner: Not yet assigned

For: RESPIRATORY SYNCYTIAL VIRUS REPLICATION INHIBITORS ✓

DATE OF DEPOSIT: March 28, 2002

I HEREBY CERTIFY THAT THIS PAPER IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS FIRST CLASS MAIL, POSTAGE PREPAID ON THE DATE INDICATED ABOVE AND IS ADDRESSED TO THE ASSISTANT COMMISSIONER FOR PATENTS, WASHINGTON, DC 20231.

Wendy A. Choi

TYPED NAME: Wendy A. Choi
REGISTRATION NO.: 36,697

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

- ☒ In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified application, within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, before the mailing date of a first Office Action on the merits of the above-identified application, or before the mailing date of a first office action after the filing of request for continued examination under §1.114, no additional fee is required.

- ☐ In accordance with §1.129(a), this Information Disclosure Statement is being filed in connection with ☐the first or ☐second After Final Submission, therefore:
- ☐ Certification in Accordance with §1.97(e) is attached; or
- ☐ The fee of \$180.00 as set forth in §1.17(p) is attached.
- ☐ In accordance with §1.97(c), this Information Disclosure Statement is being filed after the period set forth in §1.97(b) above but before the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311, or before an action that otherwise closes prosecution in the application, therefore:
- ☐ Certification in Accordance with §1.97(e) is attached; or
- ☐ The fee of \$180.00 as set forth in §1.17(p) is attached.
- ☐ In accordance with §1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311 but before, or simultaneously with, the payment of the Issue Fee, therefore included are: Certification in Accordance with §1.97(e); and the submission fee of \$180.00 as set forth in §1.17(p).
- ☒ Copies of each of the references listed on the attached Form PTO-1449 are enclosed herewith.
- ☐ Copies of references listed on the attached Form PTO-1449 are enclosed herewith EXCEPT THAT:
- ☐ In view of the voluminous nature of references [list as appropriate], and the likelihood that these references are available to the Examiner, copies are not enclosed herewith.
- ☐ In accordance with §1.98(d), copies of the following references listed on the attached Form PTO-1449 are not enclosed herewith because they were

previously cited by or submitted to the U.S. Patent and Trademark Office in patent application(s) for which a claim for priority under 35 U.S.C. §120 have been made in the instant application:


- ☐ Copies of references [list as appropriate] listed on the attached Form PTO-1449 were previously cited by or submitted to the Patent and Trademark Office in prior application Serial No. , filed .
- ☐ If any of the foregoing publications are not available to the Examiner, Applicant will endeavor to supply copies at the Examiner's request.

Please charge any deficiency or credit any overpayment to Deposit Account No. 23-3050.

This form is submitted in duplicate.

There are no listed references which are not in the English language.

Date: March 28, 2002


Wendy A. Choi
Registration No. 36,697

WOODCOCK WASHBURN LLP
One Liberty Place - 46th Floor
Philadelphia, PA 19103
Telephone: (215) 568-3100
Facsimile: (215) 568-3439

#5

Sheet 1 of 3

Form PTO-1449 ModifiedDocket No.
JANS-0028Serial No.
10/019,376List of Patent and Publications
Cited by Applicant
(Use several sheets if necessary)Applicant
Janssens et al.U.S. Department of Commerce
Patent and Trademark OfficeFiling Date
December 27, 2001Group
Not yet assigned**U. S. PATENT DOCUMENTS**

Examiner Initial		Document No.	Date	Name	Class	Subclass
	AA	4,634,704	01/06/87	Janssens et al.	514	253
	AB	4,695,569	09/22/87	Janssens et al.	514	258

FOREIGN PATENT DOCUMENTS

Examiner Initial		Document No.	Date	Country	Translation YES NO	
	AC	0 005 318 A1 ✓	11/14/79	EP		
	AD	0 099 139 A2 ✓	01/25/84	EP		
	AE	0 144 101 A2 ✓	06/12/85	EP		
	AF	0 145 037 A2 ✓	06/19/85	EP		
	AG	0 151 824 A2 ✓	08/21/85	EP		
	AH	0 151 826 A1 ✓	08/21/85	EP		
	AI	0 232 937 A2 ✓	08/19/87	EP		
	AJ	0 295 742 A1 ✓	12/21/88	EP		
	AK	0 297 661 A1 ✓	01/04/89	EP		
	AL	0 307 014 A1 ✓	03/15/89	EP		
	AM	0 747 363 A1 ✓	12/11/96	EP		

EXAMINER**DATE CONSIDERED**

RECEIVED
APR 04 2002
TECH CENTER 1600/2900

TECH CENTER 1600/2900

APR 04 2002

RECEIVED

Form PTO-1449 Modified

Docket No.
JANS-0028

Serial No.
10/019,376


Applicant
Janssens et al.

Filing Date
December 27, 2001

Group
Not yet assigned

List of Patent and Publications
Cited by Applicant
(Use several sheets if necessary)

U.S. Department of Commerce
Patent and Trademark Office



OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

AT	Akula, M. R. et al., "An Improved Synthesis of 3-Phenyl-and 3-Methoxyquinoline," <i>Org. Prep. Proced. Int.</i> , 1991 , 23, pp. 386-387
AU	Cerè, V. et al., "Catalytic Hydrogenation of Benzo[2.1.3]Oxadiazoles," <i>Tetrahedron</i> , 1972 , 28, 3271-3276
AV	Chiba, T. et al., "Inhibitory Effect of Pyridobenzazoles on Virus Replication in vitro," <i>Biol Pharm Bull</i> , 1995 , 18(8), 1081-1083
AW	Goodman and Gilman, "Biotransformation of Drugs," in <i>The Pharmacological Basis of Therapeutics</i> , 8 th ed., McGraw-Hill, Int. Ed. 1992 , 13-15
AX	Greene, T. et al., <i>Protective Groups in Organic Synthesis</i> , John Wiley & Sons Inc., 1991 , Chapter 7
AY	Lindström, S. et al., "Synthesis of the Mutagenic 2-Amino-1,6-Dimethyl-Imidazo[4,5- <i>b</i>]Pyridine (1,6-DMIP) and Five of Its Isomers," <i>Heterocycles</i> , 1994 , 38(3), 529-540
AZ	Richardson, Jr. et al. "Study of the Synthesis and Chemistry of the 5,6-Dihydroimidazo[<i>ij</i>]quinoline Series," <i>J. Org. Chem.</i> , 1960 , 25, 1138-1147
BA	Tidwell, R. et al., "Aromatic Amidines: Comparison of Their Ability to Block Respiratory Syncytial Virus Induced Cell Fusion and to Inhibit Plasmin, Urokinase, Thrombin, and Trypsin," <i>J Med Chem</i> , 1983 , 26, 294-298
BB	Wyde et al., "CL387626 exhibits marked and unusual antiviral activity against respiratory syncytial virus in tissue culture and in cotton rats," <i>Antivirus Research</i> , 1998 , 38, 31-42

EXAMINER

DATE CONSIDERED